Newsletter | February 18, 2021

02.18.21 -- Celyad CEO Talks In-House Allogeneic Cell Therapy Manufacturing

From The Editor

Good day Cell & Gene readers,


The last episode in the Business of Biotech podcast’s Cell & Gene Series that I’m guest hosting has dropped. Check out our discussion with Celyad Oncology’s CEO, Filippo Petti, on his company’s differentiated approach to the discovery and development of allogeneic CAR T-cell therapy candidates for the treatment of cancer.


The biology of cell and gene therapy will continue to evolve as the space continues to grow, and success in the clinic will always depend on success in manufacturing. ElevateBio’s CSO, Mitch Finer, Ph.D., explains why and how.


Erin Harris, editor in chief
Follow me on Twitter

Industry Insights
Regulatory Challenges For Viral Vectors For Cell And Gene Therapy

Frost & Sullivan's Virtual Think Tank series brought together leading minds in the cell and gene space to discuss current regulatory issues and key challenges in viral vector manufacturing.

Designing A Facility For Vaccine Production

Effective vaccine production facility planning combines technological innovation, streamlined workflows, and savvy budget management to ensure project speedbumps don’t become roadblocks.

COVID-19: Reducing Bottlenecks At Scalable Vaccine Production

How biopharma companies are leveraging the speed and flexibility enabled by single-use technologies and systems to navigate the maze to a vaccine against COVID-19.

From Molecule To Medicine. Delivered.

To be able to meet the growing needs of patients around the world, a company must have a strategy that can shepherd new biologics therapies throughout the development timeline.

Safely Transporting Medicines To Patients

Do pharma companies underestimate supply chain challenges? Much can go wrong when sending a therapy from A to B, but the right collaborations can mitigate risk.

Beyond mRNA Vaccines: Emerging Applications For Lipid Nanoparticle Delivery Technologies

The potential of lipid nanoparticle-based drug delivery technologies to enable a new generation of medicines was made clear in 2020 when the first two mRNA vaccines for COVID-19 were rapidly developed and authorized for emergency use. What other applications are now being explored for such delivery technologies? Dr. Jay Natarajan, director of R&D, competence center for lipid nanoparticle (LNP) technology, answers questions in this interview.

Ensuring Viral Vector Supply For Gene Therapies

The most significant challenge of gene therapies is ensuring a sufficient viral vector supply despite shortened development timelines. Cells grown in suspension are much better suited for large-scale production of viral vectors, but important considerations should be made regarding raw materials, process design, scale-up, and regulatory compliance.